Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis.
Saved in:
| Title: | Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis. |
|---|---|
| Authors: | Kuo HY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Huang TC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Chuang CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Wu TC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan., Huang YL; Department of Pathology, National Taiwan University Cancer Center, Taipei, Taiwan., Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Lee JM; Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan., Guo JC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. jhecyuanguo@gmail.com.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. jhecyuanguo@gmail.com.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. jhecyuanguo@gmail.com., Hsu CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. chihhunghsu@ntu.edu.tw.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. chihhunghsu@ntu.edu.tw.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. chihhunghsu@ntu.edu.tw. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 May 09. Date of Electronic Publication: 2026 May 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42105013 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kuo+HY%22">Kuo HY</searchLink>; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Huang+TC%22">Huang TC</searchLink>; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chuang+CH%22">Chuang CH</searchLink>; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Wu+TC%22">Wu TC</searchLink>; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.<br /><searchLink fieldCode="AU" term="%22Huang+YL%22">Huang YL</searchLink>; Department of Pathology, National Taiwan University Cancer Center, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lin+CC%22">Lin CC</searchLink>; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lee+JM%22">Lee JM</searchLink>; Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Guo+JC%22">Guo JC</searchLink>; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. jhecyuanguo@gmail.com.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. jhecyuanguo@gmail.com.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. jhecyuanguo@gmail.com.<br /><searchLink fieldCode="AU" term="%22Hsu+CH%22">Hsu CH</searchLink>; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. chihhunghsu@ntu.edu.tw.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. chihhunghsu@ntu.edu.tw.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. chihhunghsu@ntu.edu.tw. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228605732%22">Cancer immunology, immunotherapy : CII</searchLink> [Cancer Immunol Immunother] 2026 May 09. <i>Date of Electronic Publication: </i>2026 May 09. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>8605732 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0851 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203407004%22">03407004 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Immunother <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42105013 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00262-026-04408-w Languages: – Code: eng Text: English Titles: – TitleFull: Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kuo HY – PersonEntity: Name: NameFull: Huang TC – PersonEntity: Name: NameFull: Chuang CH – PersonEntity: Name: NameFull: Wu TC – PersonEntity: Name: NameFull: Huang YL – PersonEntity: Name: NameFull: Lin CC – PersonEntity: Name: NameFull: Lee JM – PersonEntity: Name: NameFull: Guo JC – PersonEntity: Name: NameFull: Hsu CH IsPartOfRelationships: – BibEntity: Dates: – D: 09 M: 05 Text: 2026 May 09 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1432-0851 Titles: – TitleFull: Cancer immunology, immunotherapy : CII Type: main |
| ResultId | 1 |
